{"entity":{"type":"insider","cik":"0001466916","url":"/insider/0001466916","json_url":"/insider/0001466916.json","name":"Byrd Scott A.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":4,"n_filings":4,"first":"2011-05-11","last":"2013-12-03","span_basis":"filed_date"},"name_variants":[{"name":"Byrd Scott A.","source":"filing","n_filings":4,"first_seen":"2011-05-11","last_seen":"2013-12-03"}],"transactions":[{"id":5043884,"accession":"0001209191-13-055053","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-13-055053","line_url":"/filing/0001209191-13-055053#line-2","is_derivative":false,"issuer_cik":"0001333248","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001333248","owner_cik":"0001466916","owner_name":"Byrd Scott A.","owner_display_name":"Byrd Scott A.","owner_url":"/insider/0001466916","role":"Officer (SVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Commercial Officer","security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7812.0,"shares_display":"7,812","price_per_share":9.16,"price_display":"9.16","price_state":"stated","total_value":71557.92,"total_display":"71,557.92","total_whole":"71,558","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-12-02","filed_date":"2013-12-03","scope":"insider"},{"id":5308757,"accession":"0001209191-13-052925","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-13-052925","line_url":"/filing/0001209191-13-052925#line-2","is_derivative":false,"issuer_cik":"0001333248","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001333248","owner_cik":"0001466916","owner_name":"Byrd Scott A.","owner_display_name":"Byrd Scott A.","owner_url":"/insider/0001466916","role":"Officer (SVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Commercial Officer","security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10416.0,"shares_display":"10,416","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":83328.0,"total_display":"83,328.00","total_whole":"83,328","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-15","filed_date":"2013-11-18","scope":"insider"},{"id":5561598,"accession":"0001209191-13-031639","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-13-031639","line_url":"/filing/0001209191-13-031639#line-3","is_derivative":false,"issuer_cik":"0001333248","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001333248","owner_cik":"0001466916","owner_name":"Byrd Scott A.","owner_display_name":"Byrd Scott A.","owner_url":"/insider/0001466916","role":"Officer (SVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Commercial Officer","security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67115.0,"shares_display":"67,115","price_per_share":7.5274,"price_display":"7.53","price_state":"stated","total_value":505201.451,"total_display":"505,201.45","total_whole":"505,201","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-06-07","filed_date":"2013-06-11","scope":"insider"},{"id":8852535,"accession":"0001209191-11-027631","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-027631","line_url":"/filing/0001209191-11-027631#line-1","is_derivative":false,"issuer_cik":"0001333248","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001333248","owner_cik":"0001466916","owner_name":"Byrd Scott A.","owner_display_name":"Byrd Scott A.","owner_url":"/insider/0001466916","role":"Officer (SVP, Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Commercial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":7.2155,"price_display":"7.22","price_state":"stated","total_value":14431.0,"total_display":"14,431.00","total_whole":"14,431","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-05-10","filed_date":"2011-05-11","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":4,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":3,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":4},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001333248","name":"CADENCE PHARMACEUTICALS INC","url":"/issuer/0001333248","role":"Officer (SVP, Chief Commercial Officer)","n_filings":4,"first_seen":"2011-05-11","last_seen":"2013-12-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001466916","retrieved_at":"2026-08-25T18:56:38+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}